

Prevalence and Management of Cardio Kidney Metabolic Disease (CKM) in the Middle East

Omer Ali^{1*}, Mustafa Jamal Ahmed¹, Anas M. Alyousef², Hani M. Sabbour³ and Hanadi Alhozali⁴

¹Department of Nephrology, Kidney Health Services, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates

²Department of Nephrology, Amiri Hospital, Kuwait City, Kuwait

³Department of Cardiology, Mediclinic Hospital, Abu Dhabi, UAE, Brown University, Warren Alpert School of Medicine, RI USA

⁴Department of Medicine, Nephrology Unit, King Abdulaziz University hospital, Jeddah, Saudi Arabia

Introduction

The Cardiovascular-Kidney-Metabolic (CKM) syndrome has emerged as a critical determinant of premature morbidity and mortality. For better understanding and management, five stages have been identified based on CKM risk factors [1].

Diabetes plays a pivotal role in CKM, often leading to Diabetic Kidney Disease (DKD), End-Stage Renal Disease (ESRD), and cardiovascular (CV) complications [2,3]. Patients with diabetes are vulnerable to Heart Failure (HF), including Reduced Ejection Fraction (HFrEF) or HF with Preserved Ejection Fraction (HFpEF) [4]. Chronic Kidney Disease (CKD) severity is typically assessed using Kidney Disease Improving Global Outcomes (KDIGO) guideline, which considers estimated Glomerular Filtration Rate (eGFR) and Albumin Creatinine Ratio or albuminuria (ACR) [5]. Albuminuria is an established biomarker for CKD and a predictor of cardiovascular disease (CVD) associated risk [6]. Additional biomarkers include C-Reactive Protein (CRP), B-type Natriuretic Peptide (BNP), and N-terminal pro-B-type Natriuretic Peptide (NT pro-BNP) tests for early diagnosis of CVD and HF [6-8].

Several studies highlight global prevalence of CKM [9,10]. In the Gulf Cooperation Council (GCC) countries, Type 2 Diabetes (T2D) prevalence ranges between 7.2-11.3%, exceeding global prevalence of 8.8% and expected to increase by 96.3% by 2035 [11,12]. Additionally, this region has also exhibited a high prevalence of HF [13,14].

Management strategies of CKM include Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, Renin-Angiotensin-System Inhibitors (RASi), Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs), and nonsteroidal mineralocorticoid receptor antagonist, finerenone [1,15-18]. Finerenone, a selective nonsteroidal MRA, has demonstrated promising benefits on CV health in patients with CKD and T2D [18,19]. Guidelines recommend finerenone with RASi or SGLT2 inhibitors in high or very high-risk patients, as it reduces CKD progression and CVD, saving societal costs [20]. However, the usage of finerenone remains limited due to hyperkalemia risk, patient-based treatment nonadherence and inadequate follow-up [21].

This paper highlights finerenone usage in the Middle East, based on a virtual expert meeting. The objective of the meeting was to achieve expert consensus concerning several critical questions regarding finerenone, which included optimal timing for treatment initiation, compatibility with RASi, effectiveness in T2D patients irrespective of their eGFR levels, and managing T2D-associated HF. Additionally, the meeting also addressed potassium

monitoring timelines and barriers to finerenone adoption.

Description

On October 12, 2024, a meeting convened five Key Opinion Leaders (KOLs) from UAE, Saudi Arabia, and Kuwait, comprising cardiologists and nephrologists recognized as experts and active researchers. The meeting highlighted literature on CKM guidelines, prevalence, treatment, and barriers to finerenone adoption, followed by sharing insights on crucial questions by KOLs.

The panel extensively discussed the prevalence of CKM across these countries and agreed that diabetic patients are at high risk of developing CKM. The panel members concurred that initiating finerenone treatment during early stages can act on inflammation, thereby reducing cardiorenal risk. They also emphasized early and effective utilization of finerenone in managing CV conditions. The panel unanimously accepted the use of finerenone in addition to SGLT2 and RASi as recommended in guidelines [1,5,15,16] and also agreed that the treatments of SGLT2 inhibitors, RASi, and finerenone are additive. They emphasized the sequential/spacing addition of these three drugs for optimal benefits. The follow-ups are recommended every four weeks, and all three therapies should be introduced over the period of 12 weeks or three months. However, as per the panel members, finerenone should not be recommended to nonproteinuric T2D patients, as ongoing trials are evaluating its efficacy in nonproteinuric DKD.

Further, the panel discussed the utility of these treatments in patients with low Blood Pressure (BP). The experts agreed that the RASi could not be recommended for patients with low BP [16,22]. The experts unanimously suggested the use of finerenone along with SGLT2 in patients with low BP and proteinuria.

An emerging concern was raised by the panel on the elevated risk of CKM among the younger population, attributed to several factors such as obesity, sleep apnea, and prediabetes. Further, they highlighted that diagnosis occurs only after the manifestation of symptoms, thereby emphasizing the need for timely interventions. Therefore, to enhance early detection, the panel members recommended annual check-ups for GFR, ACR, and proBNP tests, as well as biannual assessments for key risk factors like Hb1Ac and LDL. For patients with higher LDL levels, they recommended check-ups every four to six weeks to ensure timely management.

As per the KDIGO guidelines, finerenone is recommended in patients with GFR>25 mL/min/1.73 m² and should not be prescribed when GFR<25mL/min/1.73 m² [5]. All the panel members agreed to this administration of finerenone as per KDIGO guidelines. Further, the panel also highlighted the criticality of ACR as a sensitive marker of CV disease. However, they highlighted the inconsistency of units to measure ACR across hospitals or centers, causing confusion in determining the albuminuria stage. The panel strongly recommended standardizing measurement practices to ensure clarity and accuracy. They also stressed that early detection of albuminuria, diabetes, and other related risk factors is vital for effective CKM management. Additionally, primary healthcare providers were identified as pivotal in initiating timely interventions to control the progression of CKM.

***Address for Correspondence:** Omer Ali, Department of Nephrology, Kidney Health Services, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates; E-mail: oali@icldc.ae

Copyright: © 2025 Ali O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 28 December, 2024, Manuscript No. jnt-24-156951; **Editor Assigned:** 30 December, 2024, PreQC No. P-156951; **Reviewed:** 13 January, 2025, QC No. Q-156951; **Revised:** 18 January, 2025, Manuscript No. R-156951; **Published:** 25 January, 2025, DOI: 10.37421/2161-0959.2025.15.541

The treatment of finerenone carries a potential risk of hyperkalemia, especially at the later stages of CKD. The experts emphasized the importance of potassium binders in managing elevated potassium levels. They insisted on not prescribing finerenone if potassium levels exceeded 4.8. In such instances, they recommend stabilizing potassium levels before initiating finerenone treatment. They recommended regular potassium level monitoring in these patients (once every 2-4 weeks).

According to experts, primary health care providers and General Practitioners (GPs) have become increasingly knowledgeable about the treatment options, except for a few in the UAE. These providers play a pivotal role in managing diabetic patients and initiating appropriate treatment before referring them to nephrologists or cardiologists. However, the infrastructure and instruments required for related pathological tests are unavailable in many polyclinics.

The meeting further insisted on the importance of patient awareness, stressing the need to encourage regular check-ups and medication refills. Lack of regular check-ups poses challenges in checking potassium and GFR levels. Experts highlighted that drug treatment in the GCC region runs smoothly with the insurance companies at both private and government hospitals; however, in some regions, practitioners face unavailability of drugs at government hospitals and issues with the insurance companies at private hospitals. To address these challenges, the panel suggested the engagement of GPs, stakeholders, insurance companies, and the government to promote this organ-protective medication and expand the prescribing authority for finerenone beyond nephrologists and cardiologists to include endocrinologists and GPs.

Recently, the FINEARTS-HF Phase III trial evaluated the long-term efficacy and safety of finerenone with HFmrEF and HFpEF. Finerenone was shown to reduce worsening of HF by 18% in total and by 16% in patients with HFmrEF and HFpEF at its primary endpoint [23,24].

Conclusion

Key takeaways from the meeting:

1. Early use of finerenone aids managing CV conditions.
2. Sequential/spacing addition of finerenone to SGLT2 and RASi treatments was recommended to avoid any initial dipping of eGFR (approximately 4-6 weeks).
3. Finerenone may be beneficial in T2D patients with associated CKD. Moreover, this drug also suits low BP patients and doesn't have any further restrictions on HbA1C levels.
4. Regular checkups: annually for GFR, ACR, pro-BNP; biannual for HbA1c, LDL.
5. Hyperkalemia is manageable with regular potassium monitoring.
6. The panel emphasized involving GPs, insurance companies, governments, and stakeholders to streamline finerenone administration in GCC countries.
7. More GCC studies recommended assessing CKM prevalence.

Acknowledgement

The authors thank Bayer Middle East FZE for their scientific service support sponsorship, which was provided without any input, influence, or responsibility for the content. They also extend gratitude to TaperWing Healthcare Pvt Ltd for their editorial assistance with the manuscript.

Conflict of Interest

No conflict of interest.

References

1. Ndumele, Chiadi E, Ian J. Neeland, Katherine R. Tuttle and Sheryl L. Chow, et al. "A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association." *Circulation* 148 (2023): 1636-1664.
2. Jha, Rajesh, Sara Lopez-Trevino, Haritha R. Kankanamalage and Jay C. Jha. "Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions." *Biomedicines* 12 (2024): 1098.
3. Ritchie, Rebecca H. and E. Dale Abel. "Basic mechanisms of diabetic heart disease." *Circ Res* 126 (2020): 1501-1525.
4. Cosentino, Francesco, Peter J. Grant, Victor Aboyans and Clifford J. Bailey, et al. "2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)." *Eur Heart J* 41 (2020): 255-323.
5. Stevens, Paul E, Sofia B. Ahmed, Juan Jesus Carrero and Bethany Foster, et al. "KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease." *Kidney International* 105 (2024): S117-S314.
6. Barzilay, Joshua I, Youssef MK Farag and Jeffrey Durthaler. "Albuminuria: An underappreciated risk factor for cardiovascular disease." *J Am Heart Assoc* 13 (2024): e030131.
7. Carrero, Juan Jesus, Mikael Andersson Franko, Achim Obergfell and Anders Gabrielsen, et al. "hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: A healthcare-based study." *J Am Heart Assoc* 8 (2019): e012638.
8. Dhingra, Ravi and Ramachandran S. Vasan. "Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers." *Trends Cardiovasc Med* 27 (2017): 123-133.
9. Minhas, Abdul Mannan Khan, Roy O. Mathew, Laurence S. Sperling and Vijay Nambi, et al. "Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States." *J Am Coll Cardiol* 83 (2024): 1824-1826.
10. Schechter, Meir, Cheli Melzer Cohen, Ilan Yanuv and Aliza Rozenberg, et al. "Epidemiology of the diabetes-cardio-renal spectrum: A cross-sectional report of 1.4 million adults." *Cardiovasc Diabetol* 21 (2022): 104.
11. Burki, Talha Khan. "Country in focus: Gulf region states face major health challenges from obesity and diabetes." *Lancet Diabetes Endocrinol* 4 (2016): 737-738.
12. Ogurtsova, Katherine, J. D. da Rocha Fernandes, Y. Huang and Ute Linnenkamp, et al. "IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040." *Diabetes Res Clin Pract* 128 (2017): 40-50.
13. Bragazzi, Nicola Luigi, Wen Zhong, Jingxian Shu and Arsalan Abu Much, et al. "Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017." *Eur J Prev Cardiol* 28 (2021): 1682-1690.
14. Savarese, Gianluigi, Peter Moritz Becher, Lars H. Lund and Petar Seferovic, et al. "Global burden of heart failure: A comprehensive and updated review of epidemiology." *Cardiovasc Res* 118 (2022): 3272-3287.
15. Samson, Susan L, Priyathama Vellanki, Lawrence Blonde and Elena A. Christofides, et al. "American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm—2023 update." *Endocrine Practice* 29 (2023): 305-340.
16. Mancia Chairperson, Giuseppe, Mattias Brunström, Michel Burnier and Guido Grassi, et al. "2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)." *J Hypertens* 41 (2023): 1874-2071.
17. Ndumele, Chiadi E, Janani Rangaswami, Sheryl L. Chow and Ian J. Neeland, et al. "Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association." *Circulation* 148 (2023): 1606-1635.
18. Filippatos, Gerasimos, Stefan D. Anker, Rajiv Agarwal and Luis M. Ruilope, et al. "Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial." *Circulation* 145 (2022): 437-447.

19. Bakris, George L, Rajiv Agarwal, Stefan D. Anker and Bertram Pitt, et al. "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes." *N Engl J Med* 383 (2020): 2219-2229.
20. Quist, Sara W, Alexander V. van Schoonhoven, Stephan JL Bakker and Michał Pochopiń, et al. "Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands." *Cardiovasc Diabetol* 22 (2023): 328.
21. Dev, Sandesh, Trisha K. Hoffman, Dio Kavalieratos and Paul Heidenreich, et al. "Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: A mixed-methods study." *J Am Heart Assoc* 5 (2016): e002493.
22. Chang, Tara I. and Edgar V. Lerma. "Optimizing renin-angiotensin system inhibitor use in CKD." *Clin J Am Soc Nephrol* 17 (2022): 131-133.
23. Halaseh, Rami, Andrew J. Sauer, Orly Vardeny and Mario Enrico Canonico, et al. "A fine addition: Finerenone in the evolving landscape of heart failure with preserved ejection fraction." *Heart Fail Rev* (2024): 1-5.
24. Vaduganathan, Muthiah, Brian L. Claggett, Carolyn SP Lam and Bertram Pitt, et al. "Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial." *Eur J Heart Fail* (2024).

How to cite this article: Ali, Omer, Mustafa Jamal Ahmed, Anas M. Alyousef and Hani M. Sabbour, et al. "Prevalence and Management of Cardio Kidney Metabolic Disease (CKM) in the Middle East." *J Nephrol Ther* 15 (2025): 541.